drugset / Trial / NCT05170542
The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.
NaSingle-groupOpen-labelTreatment
Summary
In this study, We investigated the efficacy and safty of camrelizumab combined with S-1 maintenance after first-line induction chemotherapy for GC. Patients without progressive disease after 4-6 weeks of first-line chemotherapy with SOX will be treated with camrelizumab combined with S-1.
Timeline
- Start
- 2021-12-24
- Primary completion
- 2025-12-24
- Completion
- 2026-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | S-1 | Small molecule | — | — |
Indications
No indication recorded.